Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$477.37 USD
+5.37 (1.14%)
Updated Aug 16, 2024 03:55 PM ET
After-Market: $477.37 0.00 (0.00%) 5:30 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$477.37 USD
+5.37 (1.14%)
Updated Aug 16, 2024 03:55 PM ET
After-Market: $477.37 0.00 (0.00%) 5:30 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Zacks News
The company’s main area of focus is cystic fibrosis (CF). The company’s lead marketed products are Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor), Symdeko/Symkevi (tezacaftor in combination with ivacaftor), Orkambi (lumacaftor in combination with ivacaftor) and Kalydeco (ivacaftor), which are collectively approved to treat the majority of the people with CF in North America, Europe and Australia. Trikafta, Vertex’s triple combination regimen, was approved by the FDA in October 2019 for the treatment of CF in people aged 12 years and older who have at least one F508del mutation. Kaftrio (brand name of Trikafta in EU) was approved in the European Union in August 2020. It is also being evaluated in younger patients in the United States. With approval of Trikafta, Vertex can address a significantly larger CF patient population — almost 90% of patients with CF — in the future. Meanwhile, Vertex is pursuing genetic therapies to address the remaining 10% of CF patients. While CF remains the main area of focus, Vertex is also developing treatments for sickle cell disease, thalassemia and pain management.
Factors Expected to Influence Akamai's (AKAM) Q4 Earnings
by Zacks Equity Research
Akamai (AKAM) benefits from the robust performance of security products and growth in Media and Carrier Division.
The Zacks Analyst Blog Highlights: Gilead, Vertex, Celgene, Alkermes and AVEO
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead, Vertex, Celgene, Alkermes and AVEO
Vertex (VRTX) Q4 Earnings Beat on Solid CF Products Sales
by Zacks Equity Research
Vertex's (VRTX) Q4 grows on earnings and revenue beat with rising demand for its CF products. Shares up.
Biotech Stock Roundup: Celgene Tops in Q4, Gilead Disappoints, ALKS & AVEO Sink
by Zacks Equity Research
Key highlights of the week were the fourth-quarter results by biotech bigwigs Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX) and Celgene (CELG).
Vertex Pharmaceuticals (VRTX) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Vertex (VRTX) delivered earnings and revenue surprises of 23.81% and 6.27%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Regeneron (REGN) to Report Q4 Earnings: Is a Beat in Store?
by Zacks Equity Research
Strong Eylea and Dupixent sales are likely to propel better-than-expected results for Regeneron (REGN) when it reports fourth-quarter results.
Qorvo (QRVO) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Qorvo (QRVO) robust mobile growth, improved progress in IDP and stringent cost control measures will benefit the company in the to-be-reported quarter.
Will Gilead (GILD) Q4 Earnings Disappoint on Weak HCV Sales?
by Zacks Equity Research
Gilead (GILD) is scheduled to report fourth-quarter results on Feb 4. Investors will likely focus on the strong HIV franchise and other pipeline updates.
Is a Beat in Store for Vertex (VRTX) This Earnings Season?
by Zacks Equity Research
On Vertex's (VRTX) fourth-quarter 2018 earnings call, investor focus will be on the sales figures of its newest CF drug, Symdeko.
Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vertex's Kalydeco Wins Health Canada Nod to Treat CF in Kids
by Zacks Equity Research
Vertex (VRTX) gains a nod from Health Canada for Kalydeco to treat cystic fibrosis (CF) in children aged 12 to less than 24 months.
Is a Beat in the Cards for Celgene (CELG) in Q4 Earnings?
by Zacks Equity Research
Investors are looking forward to Revlimid's performance and updates from the recently announced merger agreement when Celgene Corporation (CELG) reports Q4 results.
Merck KGaA Gives Vertex Rights to Two Gene-Editing Compounds
by Zacks Equity Research
Merck KGaA (MKGAF) inks an exclusive licensing agreement with Vertex for two DNA-dependent protein kinase inhibitors in the field of gene editing for six specific genetic disease indications.
Vertex Terminates COO Ian Smith on Code of Conduct Violation
by Zacks Equity Research
Vertex (VRTX) announces termination of its chief operating officer, Ian Smith, owing to violation of the company's code of conduct and values.
Vertex Pharmaceuticals (VRTX) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CELG or VRTX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CELG vs. VRTX: Which Stock Is the Better Value Option?
Biotech Stock Roundup: Amgen, Vertex Get EC Nod for Label Expansion of Drugs
by Zacks Equity Research
A low key week for the biotech sector with regular drug approvals and pipeline updates.
Vertex's Orkambi Wins EU Nod to Treat Cystic Fibrosis in Kids
by Zacks Equity Research
Vertex (VRTX) gains an EU approval for Orkambi to treat 2-5-year-old children suffering cystic fibrosis (CF).
Moderna (MRNA) Announces Pipeline Progress, Shares Rise
by Zacks Equity Research
Modern's pipeline of mRNA candidates, which are being developed for several cancer indications and rare diseases, is progressing well.
Vertex, CRISPR's Sickle Disease Drug Gets FDA's Fast Track Tag
by Zacks Equity Research
FDA grants a Fast Track designation to Vertex (VRTX) and CRISPR Therapeutics' gene editing candidate, CTX001, for the treatment of sickle cell disease.
Vertex Joins Forces With Arbor to Build Gene-Editing Therapies
by Zacks Equity Research
Vertex (VRTX) inks a collaboration deal with small biotech entity Arbor to discover novel proteins for progressing discovery of gene-editing therapies to tackle serious ailments.
The Zacks Analyst Blog Highlights: Amgen, Aduro, Vertex, Evofem and Incyte
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amgen, Aduro, Vertex, Evofem and Incyte
Biotech Stock Roundup: Pipeline Updates From VRTX & AMGN, ADRO Teams Up With LLY
by Zacks Equity Research
A busy week for the biotech sector with quite a few licensing deals and other regulatory updates.
Vertex's (VRTX) 3rd Study on Pain Drug Meets Primary Endpoint
by Zacks Equity Research
Vertex (VRTX) reports positive phase II data of its pipeline candidate VX-150 in patients with pain caused by small fiber neuropathy.
5 Drug/Biotech Stocks With Promise to Sustain Bull Run in 2019
by Zacks Equity Research
The big drug stocks are on a strong footing of late. Here are five such picks from the biotech and large-cap pharma space that are expected to do well in 2019 too.